DAWN Day One Biopharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and commercialization of targeted oncologic therapies for pediatric and adult patients with life-threatening diseases, focusing on breakthrough medicines
• • New emphasis: Commercial launch of FDA-approved OJEMDA (tovorafenib) for relapsed/refractory pediatric low-grade glioma, only once-weekly systemic pLGG therapy

Risk Factors

• • Regulatory risk: Dependency on FDA approval and exclusivity for OJEMDA, with increased product revenue $155.4M driven by U.S. sales
• • Macroeconomic risk: Potential impact from global economic volatility, inflation, trade barriers, and geopolitical conflicts affecting capital raising efforts

Risk Factors

• • New licensing risk: Acquisition of DAY301 license from MabCare Therapeutics in June 2024 adds development and commercialization uncertainties
• • Updated financial risk: Net loss increased to $86.0 million for nine months ended Sept 30, 2025 vs $29.8 million prior year, reflecting higher R&D and commercialization costs

What are the latest DAWN SEC filings in 2026?

Day One Biopharmaceuticals, Inc. (DAWN) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DAWN file its most recent 10-K annual report?

Day One Biopharmaceuticals, Inc. (DAWN) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DAWN 10-Q quarterly reports?

Day One Biopharmaceuticals, Inc. (DAWN)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every DAWN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DAWN filed recently?

Day One Biopharmaceuticals, Inc. (DAWN)'s most recent 8-K was filed on April 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DAWN insider trading activity (Form 4)?

SignalX aggregates every DAWN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DAWN file with the SEC?

Day One Biopharmaceuticals, Inc. (DAWN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DAWN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Day One Biopharmaceuticals, Inc. (DAWN).

What is DAWN's SEC CIK number?

Day One Biopharmaceuticals, Inc. (DAWN)'s SEC CIK (Central Index Key) number is 1845337. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1845337 to look up all DAWN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DAWN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Day One Biopharmaceuticals, Inc. (DAWN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.